CLAIMS
1. A compound of the formula (I):
(Formula Removed)
wherein
Z is Het2, optionally substituted on a ring carbon atom with one or more substituents selected from the group consisting of halo, cyano, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, (C3-C8)cycloalkyl, (C3-C8)cycloalkyl(C1-C4)alkyl, (C1-C4)alkyl-S-, amino, (C1-C4)alkylamino, di(C1-C4)alkylamino, amino(C1-C4)alkyl, (C1-C4)alkylamino(C1-C4)alkyl, and di[(C1-C4)alkyl]amino(C1-C4)alkyl; and/or Het2 is optionally substituted on a ring nitrogen atom with (C1-C4)alkyl, halo(C1-C4)alkyl and (C3-C8)cycloalkyl; with the proviso that Z is not tetrazolyl;
Y1, Y2, Y3 and Y4 are each independently CH, CR1 or N, provided that no more than two of Y1, Y2, Y3 and Y4 are N;
each R1 is independently selected from the group consisting of halo, cyano, amino, hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, (C1-C4)alkoxy(C1-C4)alkyl, -C(O)H, -C(O)(C1-C4)alkyl, and -C(O)N(R2)2;
each R2 is independently hydrogen, (C1-C4)alkyl, halo(C1-C4)alkyl, hydroxy(C1-C4)alkyl, or (C3-C6)cycloalkyl; or, where a nitrogen is substituted with two R2 groups, each independently selected from (C1-C4)alkyl, halo(C1-C4)alkyl, or hydroxy(C1-C4)alkyl, they may be taken together with the N atom

to which they are attached to form a 4- to 6-membered ring which, when so
formed, may therefore optionally be substituted with hydrogen, alkyl, halo,
hydroxy, hydroxyalkyl or haloalkyl;
B is phenyl or Het2, wherein, when B is Het2 it is attached to the oxy linker at a ring carbon atom, and wherein B is optionally further substituted on a ring carbon atom with one or more substituents selected from the group consisting of halo, cyano, hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, cyano(C1-C4)alkyl, amino, (C1-C4)alkylamino, di(C1-C4)alkylamino, amino(C1-C4)alkyl, (C1-C4)alkylamino(C1-C4)alkyl, di[(C1-C4)alkyl]amino(C1-C4)alkyl, trifluoromethylthio, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, -C(O)R2, -C(O)OR2, -OC(O)R2, -C(O)-N(R2)2, -CH2-C(O)R2, - CH2-C(O)OR2, -CH2-OC(O)R2, -CH2-C(O)-N(R2)2) S(O)2R2, S(O)2N(R2)2, (C3-C8)cycloalkyl, and (C3-C8)cycloalkyl(C1-C4)alkyl; and/or
Het2 is optionally substituted on a ring nitrogen atom with a substituent selected from the group consisting of (C1-C4)alkyl, halo(C1-C4)alkyl, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, amino(C1-C4)alkyl, (C1-C4)alkylamino(C1-C4)alkyl, di[(C1-C4)alkyl]amino(C1-C4)alkyl, -CH2-C(O)R2, -CH2-C(O)OR2, -CH2-C(O)-N(R2)2, S(O)2R2, and S(O)2N(R2)2;
X is absent, -O-, methylene, ethylene, methylene-O-, or -O-methylene;
C is (C3-C8)cycloalkyl, Het1, phenyl, or Het2, each optionally substituted on a ring carbon atom with one or more substituents selected from the group consisting of halo, cyano, hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, N(R2)2, (R2)2N(C1-C4)alkyl, trifluoromethylthio, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, -C(O)R2, -C(O)OR2, -OC(O)R2, -C(O)-N(R2)2, -CH2-C(O)R2, - CH2-C(O)OR2, -CH2-OC(O)R2, -CH2-C(O)-N(R2)2, S(O)2R2, S(O)2N(R2)2, (C3-C8)cycloalkyl(C1-C4)alkyl, (C3-C8)cycloalkoxy, (C3-C8)cycloalkylamino, (C3-C8)cycloalkylamino(C1-C4)alkyl, (C3-C8)cycloalkyl(C1-C4)alkylamino, (C3-C8)cycloalkyl(C1-C4)alkylamino(C1-C4)alkyl, (C3-C8)cycloalkyl(C1-C4)alkoxy and D; and/or

Het2 is optionally substituted on a ring nitrogen atom with a substituent
selected from the group consisting of hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl,
amino (C1-C4)alkyl, (C1-C4)alkylamino(C1-C4)alkyl, di[(C1-C4)alkyl]amino(C1-
C4)alkyl, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, -C(O)R2, -C(O)OR2,
-CH2-C(O)R2, -CH2-C(O)OR2,-CH2-C(O)-N(R2)2) S(O)2R2, and S(O)2N(R2)2
and D;
with the proviso that C is not 3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl;
D is phenyl, benzyl, (C3-C8)cycloalkyl, or Het1, each optionally substituted on a carbon atom with one or more substituents independently selected from the group consisting of halo, cyano, hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, amino, (C1-C4)alkylamino, di(C1-C4)alkylamino, amino(C1-C4)alkyl, (C1-C4)alkylamino(C1-C4)alkyl, di[(C1-C4)alkyl]amino(C1-C4)alkyl, trifluoromethylthio, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl,-C(O)R2, -C(O)OR2, -OC(O)R2, -C(O)-N(R2)2l -CH2-C(O)R2, -CH2-C(O)OR2, -CH2-OC(O) R2, -CH2-C(O)-N(R2)2, S(O)2R2, and S(O)2N(R2)2;
Het1 is a 3- to 8-membered, saturated or partially unsaturated monocyclic heterocyclic group comprising one or two or three ring members selected from -NR3-, -O-, -C(O)- and -S(O)p-;
R3 is either the point of attachment to X or C to give
(Formula Removed)
or R3 is selected from the group consisting of hydrogen, (C1-C4)alkyl, halo(C1-C4)alkyl, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, -C(O)(C1-C4)alkyl, -C(O)O(C1-C4)alkyl,-CH2-C(O)O(C1-C4)alkyl,-CH2-C(O)-N((C1-C4)alkyl)2, S(O)2R2, S(O)2N(R2)2 and (C3-C8)cycloalkyl;
p is 0, 1 or 2; and

Het2 is a 5- or 6-membered aromatic heterocyclic group comprising either (a) 1 to 4 nitrogen atoms, (b) one oxygen or one sulphur atom or (c) 1 oxygen atom or 1 sulphur atom and 1 or 2 nitrogen atoms;
or a tautomer thereof, or a pharmaceutically acceptable salt or solvate of the compound of formula (I), or its tautomer;
with the proviso that the compound of formula (I) is not the following specific compound:
(Formula Removed)
2. A compound of formula (I), or a pharmaceutically acceptable salt,
solvate or tautomer thereof, as claimed in Claim 1, wherein Z is not
isoxazolyl.
3. A compound of formula (I), or a pharmaceutically acceptable salt,
solvate or tautomer thereof, as claimed in Claim 1 of Claim 2, wherein Z is
selected from the group consisting of 2-thiazolyl, 4-thiazolyl, 1-thia-3,4-
diazolyl or 1-thia-2,4-diazolyl, pyridinyl, pyrazinyl, pyridazinyl, or pyrimidinyl.
4. A compound of formula (I), or a pharmaceutically acceptable salt,
solvate or tautomer thereof, as claimed in any preceding claim, wherein Y1 is
CR1, and Y2, Y3 and Y4 are each CH; or Y1 and Y3 are CR1 and Y2 and Y4
are CH.
5. A compound of formula (I), or a pharmaceutically acceptable salt,
solvate or tautomer thereof, as claimed in any preceding claim, wherein
each R1 is independently selected from halo; cyano; (C1-C4)alkyl; halo(C1-
C4)alkyl; (C1-C4)alkoxy; and -C(O)NH2.

6. A compound of formula (I), or a pharmaceutically acceptable salt, solvate or tautomer thereof, as claimed in any preceding claim, wherein B is phenyl.
7. A compound of formula (I), or a pharmaceutically acceptable salt, solvate or tautomer thereof, as claimed in any preceding claim, wherein B is unsubstituted, or is substituted on a ring carbon with one or two substituents independently selected from the group consisting of halo; halo(C1-C4)alkyl; or halo(C1-C4)alkoxy.
8. A compound of formula (I), or a pharmaceutically acceptable salt, solvate or tautomer thereof, as claimed in any preceding claim, wherein the C ring, at the atom where it attaches to X, or directly to ring B if X is absent, is not further substituted except that such an atom may be substituted by hydrogen if chemically possible
9. A compound of formula (I), or a pharmaceutically acceptable salt, solvate or tautomer thereof, as claimed in any preceding claim, wherein C is selected from the group consisting of pyrazolyl; pyridinyl; pyridazinyl; pyrimidinyl; azetidinyl; piperidinyl; or tetrahydropyranyl.
10. A compound of formula (I), or a pharmaceutically acceptable salt, solvate or tautomer thereof, as claimed in any preceding claim, wherein X is absent.
11. A compound of formula (I), or a pharmaceutically acceptable salt, solvate or tautomer thereof as claimed in any preceding claim, which has the formula (lb):

(Formula Removed)
wherein Ra is independently selected from the group consisting of halo,
cyano, hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-
C4)alkoxy, cyano(C1-C4)alkyl, amino, (C1-C4)alkylamino, di(C1-
C4)alkylamino, amino(C1-C4)alkyl, (C1-C4)alkylamino(C1-C4)alkyl, di[(C1-
C4)alkyl]amino(C1-C4)alkyl, trifluoromethylthio, hydroxy(C1-C4)alkyl, (C1-
C4)alkoxy(C1-C4)alkyl, -C(O)R2, -C(O)OR2, -OC(O)R2, -C(O)-N(R2)2, -
CH2-C(O)R2, - CH2-C(O)OR2, -CH2-OC(O)R2, -CH2-C(O)-N(R2)2,
S(O)2R2, S(O)2N(R2)2, (C3-C8)cycloalkyl, and (C3-C8)cycloalkyl(C1-
C4)alkyl;
and
n is 0, 1 or 2.
12. A compound of formula (I), or a pharmaceutically acceptable salt,
solvate or tautomer thereof, as claimed in any preceding claim, selected
from the group consisting of: 4-[2-(6-Aminopyridin-3-yl)-4-fluorophenoxy]-N-(5-chloro-1,3-thiazol-2-yl)-3-
cyanobenzenesulfonamide; 5-chloro-4-(4-chloro-2-piperidin-4-ylphenoxy)-2-fluoro-N-1,3-thiazol-4-
ylbenzenesulfonamide; 4-[4-Chloro-2-(1H-pyrazol-4-yl)phenoxy]-3-cyano-A/-1,3-thiazol-2-
ylbenzenesulfonamide; 3-cyano-4-[2-(1-methyl-1H-pyrazol-5-yl)-4-(trifluoromethoxy)phenoxy]-N-1,3-
thiazol-2-ylbenzenesulfonamide; 4-(2-azetidin-3-yl-4-chlorophenoxy)-5-chloro-N-(5-chloro-1,3-thiazol-2-yl)-2-
fluorobenzenesulfonamide;

N-(5-Chloro-1,3-thiazol-2-yl)-3-cyano-4-[4-fluoro-2-(1H-pyrazol-4-
yl)phenoxy]benzenesulfonamide; N-(5-Chloro-1,3-thiazol-2-yl)-3-cyano-4-[4-chloro-2-(1H-pyrazol-4-
yl)phenoxy]benzenesulfonamide; 4-[2-(2-aminopyridin-4-yl)-4-chlorophenoxy]-2,5-difluoro-N-1,2,4-thiacliazol-5-
ylbenzenesulfonamide; 4-[2-(5-amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-
thiazol-4-ylbenzenesulfonamide; 2,5-difluoro-4-[2-(1H-pyrazol-5-yl)-4-(trifluoromethyl)phenoxy]-N-1,2,4-
thiadiazol-5-ylbenzenesulfonamide; 2,5-difluoro-4-[2-(1H-pyrazol-4-yl)-4-(trifluoromethyl)phenoxy]-N-1,2,4-
thiadiazol-5-ylbenzenesulfonamide; 4-(4-chloro-2-(1H-pyrazol-4-yl)phenoxy)-3-cyano-N-(1,2,4-thiadiazol-5-
yl)benzenesulfonamide; 4-[2-(5-amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-3-cyano-N-1,2,4-thiadiazol-
5-ylbenzenesulfonamide; 3-cyano-4-[2-(1H-pyrazol-5-yl)-4-(trifluoromethoxy)phenoxy]-N-1,2,4-
thiadiazol-5-ylbenzenesulfonamide; 4-[2-(5-amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,2,4-
thiadiazol-5-ylbenzenesulfonamide; 3-cyano-4-[2-(1 -methyl-1 H-pyrazol-5-yl)-4-(trifluoromethoxy)phenoxy]-N-1,2,4-
thiadiazol-5-ylbenzenesulfonamide; 5-chloro-4-(4-chloro-2-piperidin-4-ylphenoxy)-2-fluoro-N-1,2,4-thiadiazol-5-
ylbenzenesulfonamide; 3-cyano-4-[2-(5-methyl-1H-pyrazol-4-yl)-4-(trifluoromethyl)phenoxy]-N-1,2,4-
thiadiazol-5-ylbenzenesulfonamide; 4-{2-[2-(aminomethyl)pyridin-4-yl]-4-chlorophenoxy}-5-chloro-2-fluoro-N-1,2,4-
thiadiazol-5-ylbenzenesulfonamide; 3-Cyano-4-[2-(tetrahydro-2H-pyran-4-yl)-4-(trifluoromethyl)phenoxy]-N-1,2,4-
thiadiazol-5-ylbenzenesulfonamide; 5-Chloro-2-fluoro-N-(5-fIuoropyridin-2-yl)-4-[2-piperidin-4-yl-4-
(trifluoromethyl)phenoxy]benzenesulfonamide;

4-[2-(1-azetidin-3-yl-1H-pyrazol-5-yl)-4-chlorophenoxy]-2,5-difluoro-N-1,2,4-
thiadiazol-5-ylbenzenesulfonamide; 3-cyano-4-[2-pyridazin-4-yl-4-(trifluoromethyl)phenoxy]-N-1,2,4-thiadiazol-5-
ylbenzenesulfonamide; 4-[2-(5-amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3,4-
thiadiazol-2-ylbenzenesulfonamide; 4-[4-chloro-5-fluoro-2-(1H-pyrazol-4-yl)phenoxy]-3-cyano-N-1,2,4-thiadiazol-5-
ylbenzenesulfonamide; 2,5-difluoro-4-[2-pyridazin-4-yl-4-(trifluoromethyl)phenoxy]-N-1,2,4-thiadiazol-
5-ylbenzenesulfonamide; 5-Chloro-2-fluoro-4-{4-fluoro-2-[1 -(1 -methylazetidin-3-yl)-1 H-pyrazol-5-
yl]phenoxy}-N-1,2,4-thiadiazol-5-ylbenzenesulfonamide; 5-Chloro-2-fluoro-4-{4-fluoro-2-[1-(1-methylazetidin-3-yl)-1H-pyrazol-5-
yl]phenoxy}-N-1,3-thiazol-4-ylbenzenesulfonamide; 4-[2-(1-Azetidin-3-yl-1H-pyrazol-5-yl)-4-fluorophenoxy]-5-chloro-2-fluoro-N-
1,3-thiazol-4-ylbenzenesulfonamide; 4-[2-(1-azetidin-3-yl-1 H-pyrazol-5-yl)-4-chlorophenoxy]-3-cyano-N-1,3-thiazol-
4-ylbenzenesulfonamide; 4-[2-(1-azetidin-3-yl-1H-pyrazol-5-yl)-4-fluorophenoxy]-5-chloro-2-fluoro-N-
1,2,4-thiadiazol-5-ylbenzenesulfonamide; 4-{4-Chloro-2-[1 -(1 -methylazetidin-3-yl)-1 H-pyrazol-5-yl]phenoxy}-2,5-difluoro-
N-1,2,4-thiadiazol-5-ylbenzenesulfonamide; 4-[2-(2-aminopyridin-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-pyrimidin-4-
ylbenzenesulfonamide; 5-chloro-4-[4-chloro-2-(1-methyl-1H-pyrazol-5-yl)phenoxy]-2-fluoro-N-
pyrimidin-4-ylbenzenesulfonamide; 4-[2-(2-aminopyridin-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3,4-
thiadiazol-2-ylbenzenesulfonamide; 3-cyano-4-[2-pyridazin-4-yl-4-(trifluoromethoxy)phenoxy]-N-1,2,4-thiadiazol-5-
ylbenzenesulfonamide, 4-{4-Chloro-2-[2-(dimethylamino)pyridin-4-yl]phenoxy}-3-cyano-N-1,2,4-
thiadiazol-5-ylbenzenesulfonamide;

2,5-Difluoro-4-{2-[1 -(1 -methylazetidin-3-yl)-1 H-pyrazol-5-yl]-4-
(trifluoromethyl)phenoxy}-N-1,3-thiazol-4-ylbenzenesulfonamide;
4-{4-Chloro-2-[1-(1-ethylazetidin-3-yl)-1H-pyrazol-5-yl]phenoxy}-3-cyano-N-
1,3-thiazol-4-ylbenzenesulfonamide; 4-{4-Chloro-2-[2-(cyclobutyloxy)pyridin-4-yl]phenoxy}-3-cyano-N-1,2,4-
thiadiazol-5-ylbenzenesulfonamide; 4-{4-Chloro-2-[2-(dimethylamino)pyridin-4-yl]phenoxy}-3-cyano-N-1,2,4-
thiadiazol-5-ylbenzenesulfonamide; 5-chloro-2-fluoro-4-[2-pyridazin-4-yl-4-(trifluoromethyl)phenoxy]-N-1,3,4-
thiadiazol-2-ylbenzenesulfonamide; 4-[2-(3-amino-1H-pyrazol-4-yl)-4-(trifluoromethyl)phenoxy]-5-chloro-2-fluoro-
N-1,3,4-thiadiazol-2-ylbenzenesulfonamide; 4-[2-(3-amino-1H-pyrazol-4-yl)-4-(trifluoromethyl)phenoxy]-5-chloro-2-fluoro-
N-1,3-thiazol-4-ylbenzenesulfonamide; 4-[4-Ch)oro-2-(2-piperazin-1-ylpyrimidin-4-yl)phenoxy]-3-cyano-N-1,2,4-thiadiazol-5-ylbenzenesulfonamide; 4-[2-(2-aminopyridin-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-pyridazin-3-
ylbenzenesulfonamide; 4-{2-[2-(Azetidin-1-ylmethyl)pyridin-4-yl]-4-chlorophenoxy}-2,5-difluoro-N-1,3-
thiazol-4-ylbenzenesulfonamide; 3-Cyano-4-{2-[1-(1-ethylazetidin-3-yl)-1H-pyrazol-5-yl]-4-
(trifluoromethyl)phenoxy}-N-1,2,4-thiadiazol-5-ylbenzenesulfonamide; 5-Chloro-2-fluoro-4-[5-fluoro-2-pyridazin-4-yl-4-(trifluoromethyl)phenoxy]-N-
1,3,4-thiadiazol-2-ylbenzenesulfonamide; 3-Cyano-4-[5-fluoro-2-pyridazin-4-yl-4-(trifluoromethyl)phenoxy]-N-1,2,4-
thiodiazol-5-ylbenzenesulfonamide; 4-[2-(3-amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-
pyrimidin-4-ylbenzenesulfonamide; 2-fluoro-5-methyl-4-[2-pyridazin-4-yl-4-{trifluoromethoxy)phenoxy]-N-1,3,4-thiadiazol-2-ylbenzenesulfonamide; and 4-[2-(3-amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-
pyridazin-3-ylbenzenesulfonamide.; and

4-[2-(3-amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-
pyrimidin-2-ylbenzenesulfonamide.
13. A pharmaceutical composition comprising a compound of formula (I),
or a pharmaceutically acceptable salt, solvate or tautomer thereof, as claimed
in any of Claims 1 to 12, and one or more pharmaceutically acceptable
excipients.
14. A pharmaceutical composition as claimed in Claim 13 comprising one or more additional therapeutic agents.
15. A compound of the formula (I):
(Formula Removed)
wherein
Z is Het2, optionally substituted on a ring carbon atom with one or more substituents selected from the group consisting of halo, cyano, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, (C3-C8)cycloalkyl, (C3-C8)cycloalkyl(C1-C4)alkyl, (C1-C4)alkyl-S-, amino, (C1-C4)alkylamino, di(C1-C4)alkylamino, amino(C1-C4)alkyl, (C1-C4)alkylamino(C1-C4)alkyl, and di[(C1-C4)alkyl]amino(C1-C4)alkyl; and/or Het2 is optionally substituted on a ring nitrogen atom with (C1-C4)alkyl, halo(C1-C4)alkyl and (C3-C8)cycloalkyl; with the proviso that Z is not tetrazolyl;
Y1, Y2, Y3 and Y4 are each independently CH, CR1 or N, provided that no more than two of Y1, Y2, Y3 and Y4 are N;

each R1 is independently selected from the group consisting of halo, cyano,
amino, hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, hydroxy(C1-C4)alkyl, (C1-
C4)alkoxy, halo(C1-C4)alkoxy, (C1-C4)alkoxy(C1-C4)alkyl, -C(O)H, -C(O)(C1-
C4)alkyl, and -C(O)N(R2)2;
each R2 is independently hydrogen, (C1-C4)alkyl, halo(C1-C4)alkyl, hydroxy(C1-C4)alkyl, or (C3-C6)cycloalkyl; or, where a nitrogen is substituted with two R2 groups, each independently selected from (C1-C4)alkyl, halo(C1-C4)alkyl, or hydroxy(C1-C4)alkyl, they may be taken together with the N atom to which they are attached to form a 4- to 6-membered ring which, when so formed, may therefore optionally be substituted with hydrogen, alkyl, halo, hydroxy, hydroxyalkyl or haloalkyl;
B is phenyl or Het2, wherein, when B is Het2 it is attached to the oxy linker at a ring carbon atom, and wherein B is optionally further substituted on a ring carbon atom with one or more substituents selected from the group consisting of halo, cyano, hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, cyano(C1-C4)alkyl, amino, (C1-C4)alkylamino, di(C1-C4)alkylamino, amino(C1-C4)alkyl, (C1-C4)alkylamino(C1-C4)alkyl, di[(C1-C4)alkyl]amino(C1-C4)alkyl, trifluoromethylthio, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, -C(O)R2, -C(O)OR2, -OC(O)R2, -C(O)-N(R2)2, -CH2-C(O)R2, - CH2-C(O)OR2, -CH2-OC(O)R2, -CH2-C(O)-N(R2)2, S(O)2R2, S(O)2N(R2)2, (C3-C8)cycloalkyl, and (C3-C8)cycloalkyl(C1-C4)alkyl; and/or
Het2 is optionally substituted on a ring nitrogen atom with a substituent selected from the group consisting of (C1-C4)alkyl, halo(C1-C4)alkyl, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, amino{C1-C4)alkyl, (C1-C4)alkylamino(C1-C4)alkyl, di[(C1-C4)alkyl]amino(C1-C4)alkyl, -CH2-C(O)R2, -CH2-C(O)OR2, -CH2-C(O)-N(R2)2, S(O)2R2, and S(O)2N(R2)2;
X is absent, -O-, methylene, ethylene, methylene-O-, or -O-methylene;
C is (C3-C8)cycloalkyl, Het1, phenyl, or Het2, each optionally substituted on a ring carbon atom with one or more substituents selected from the group

consisting of halo, cyano, hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-
C4)alkoxy, halo(C1-C4)alkoxy, N(R2)2, (R2)2N(C1-C4)alkyl, trifluoromethylthio,
hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, -C(O)R2, -C(O)OR2, -
OC(O)R2, -C(O)-N(R2)2, -CH2-C(O)R2, - CH2-C(O)OR2, -CH2-OC(O)R2, -
CH2-C(O)-N(R2)2, S(O)2R2, S(O)2N(R2)2, (C3-C8)cycloalkyl(C1-C4)alkyl, (C3-
C8)cycloalkoxy, (C3-C8)cycloalkylamino, (C3-C8)cycloalkylamino(C1-C4)alkyl,
(C3-C8)cycloalkyl(C1-C4)alkylamino, (C3-C8)cycloalkyl(C1-C4)alkylamino(C1-
C4)alkyl, (C3-C8)cycloalkyl(C1-C4)alkoxy and D; and/or
Het2 is optionally substituted on a ring nitrogen atom with a substituent selected from the group consisting of hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, amino(C1-C4)alkyl, (C1-C4)alkylamino(C1-C4)alkyl, di[(C1-C4)alkyl]amino(C1-C4)alkyl, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, -C(O)R2, -C(O)OR2, -CH2-C(O)R2, -CH2-C(O)OR2,-CH2-C(O)-N(R2)2, S(O)2R2, and S(O)2N(R2)2 and D;
with the proviso that C is not 3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl;
D is phenyl, benzyl, (C3-C8)cycloalkyl, or Het1, each optionally substituted on a carbon atom with one or more substituents independently selected from the group consisting of halo, cyano, hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, amino, (C1-C4)alkylamino, di(C1-C4)alkylamino, amino(C1-C4)alkyl, (C1-C4)alkylamino(C1-C4)alkyl, di[(C1-C4)alkyl]amino(C1-C4)alkyl, trifluoromethylthio, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl,-C(O)R2, -C(O)OR2, -OC(O)R2, -C(O)-N(R2)2) -CH2-C(O)R2, -CH2-C(O)OR2, -CH2-OC(O) R2, -CH2-C(O)-N(R2)2, S(O)2R2, and S(O)2N(R2)2;
Het1 is a 3- to 8-membered, saturated or partially unsaturated monocyclic heterocyclic group comprising one or two or three ring members selected from -NR3-, -O-, -C(O)- and -S(O)p-;
R3 is either the point of attachment to X or C to give

(Formula Removed)
or R3 is selected from the group consisting of hydrogen, (C1-C4)alkyl, halo(C1-C4)alkyl, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, -C(O)(C1-C4)alkyl, -C(O)O(C1-C4)alkyl,-CH2-C(O)O(C1-C4)alkyl,-CH2-C(O)-N((C1-C4)alkyl)2, S(O)2R2, S(O)2N(R2)2 and (C3-C8)cycloalkyl;
p is 0,1 or 2; and
Het2 is a 5- or 6-membered aromatic heterocyclic group comprising either (a) 1 to 4 nitrogen atoms, (b) one oxygen or one sulphur atom or (c) 1 oxygen atom or 1 sulphur atom and 1 or 2 nitrogen atoms;
or a tautomer thereof, or a pharmaceutically acceptable salt or solvate of the compound of formula (I), or its tautomer;
or a compound as defined in any one of Claims 1 to 10, or a pharmaceutically acceptable salt, solvate or tautomer thereof;
for use as a medicament.
16. A compound of the formula (I):
(Formula Removed)
wherein

Z is Het2, optionally substituted on a ring carbon atom with one or more
substituents selected from the group consisting of halo, cyano, (C1-C4)alkyl,
halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, (C3-C8)cycloalkyl, (C3-
C8)cycloalkyl(C1-C4)alkyl, (C1-C4)alkyl-S-, amino, (C1-C4)alkylamino, di(C1-
C4)alkylamino, amino(C1-C4)alkyl, (C1-C4)alkylamino{C1-C4)alkyl, and di[(C1-
C4)alkyl]amino(C1-C4)alkyl; and/or Het2 is optionally substituted on a ring
nitrogen atom with (C1-C4)alkyl, halo(C1-C4)alkyl and (C3-C8)cycloalkyl; with
the proviso that Z is not tetrazolyl;
Y1, Y2, Y3 and Y4 are each independently CH, CR1 or N, provided that no more than two of Y1, Y2, Y3 and Y4 are N;
each R1 is independently selected from the group consisting of halo, cyano, amino, hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, (C1-C4)alkoxy(C1-C4)alkyl, -C(O)H, -C(O)(C1-C4)alkyl, and -C(O)N(R2)2;
each R2 is independently hydrogen, (C1-C4)alkyl, halo(C1-C4)alkyl, hydroxy(C1-C4)alkyl, or (C3-C6)cycloalkyl; or, where a nitrogen is substituted with two R2 groups, each independently selected from (C1-C4)alkyl, halo(C1-C4)alkyl, or hydroxy(C1-C4)alkyl, they may be taken together with the N atom to which they are attached to form a 4- to 6-membered ring which, when so formed, may therefore optionally be substituted with hydrogen, alkyl, halo, hydroxy, hydroxyalkyl or haloalkyl;
B is phenyl or Het2, wherein, when B is Het2 it is attached to the oxy linker at a ring carbon atom, and wherein B is optionally further substituted on a ring carbon atom with one or more substituents selected from the group consisting of halo, cyano, hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, cyano(C1-C4)alkyl, amino, (C1-C4)alkylamino, di{C1-C4)alkylamino, amino(C1-C4)alkyl, (C1-C4)alkylamino(C1-C4)alkyl, di[(C1-C4)alkyl]amino(C1-C4)alkyl, trifluoromethylthio, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, -C(O)R2, -C(O)OR2, -OC(O)R2, -C(O)-N(R2)2, -

CH2-C(O)R2, - CH2-C(O)OR2, -CH2-OC(O)R2, -CH2-C(O)-N(R2)2, S(O)2R2,
S(O)2N(R2)2, (C3-C8)cycloalkyl, and (C3-C8)cycloalkyl(C1-C4)alkyl; and/or
Het2 is optionally substituted on a ring nitrogen atom with a substituent
selected from the group consisting of (C1-C4)alkyl, halo(C1-C4)alkyl,
hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, amino(C1-C4)alkyl, (C1-
C4)alkylamino(C1-C4)alkyl, di[(C1-C4)alkyl]amino(C1-C4)alkyl, -CH2-C(O)R2, -
CH2-C(O)OR2, -CH2-C(O)-N(R2)2, S(O)2R2, and S(O)2N(R2)2;
X is absent, -O-, methylene, ethylene, methylene-O-, or -O-methylene;
C is (C3-C8)cycloalkyl, Het1, phenyl, or Her2, each optionally substituted on a ring carbon atom with one or more substituents selected from the group consisting of halo, cyano, hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, N(R2)2, (R2)2N(C1-C4)alkyl, trifluoromethylthio, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, -C(O)R2, -C(O)OR2, -OC(O)R2, -C(O)-N(R2)2, -CH2-C(O)R2, - CH2-C(O)OR2, -CH2-OC(O)R2, -CH2-C(O)-N(R2)2, S(O)2R2, S(O)2N(R2)2, (C3-C8)cycloalkyl(C1-C4)alkyl, (C3-C8)cycloalkoxy, (C3-C8)cycloalkylamino, (C3-C8)cycloalkylamino(C1-C4)alkyl, (C3-C8)cycloalkyl(C1-C4)alkylamino, (C3-C8)cycloalkyl(C1-C4)alkylamino(C1-C4)alkyl, (C3-C8)cycloalkyl(C1-C4)alkoxy and D; and/or
Het2 is optionally substituted on a ring nitrogen atom with a substituent selected from the group consisting of hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, amino(C1-C4)alkyl, (C1-C4)alkylamino(C1-C4)alkyl, di[(C1-C4)alkyl]amino(d-C4)alkyl, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, -C(O)R2, -C(O)OR2, -CH2-C(O)R2, -CH2-C(O)OR2,-CH2-C(O)-N(R2)2, S(O)2R2, and S(O)2N(R2)2 and D;
D is phenyl, benzyl, (C3-C8)cycloalkyl, or Het1, each optionally substituted on a carbon atom with one or more substituents independently selected from the group consisting of halo, cyano, hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, amino, (C1-C4)alkylamino, di(d-d)alkylamino, amino(C1-C4)alkyl, (C1-C4)alkylamino(C1-C4)alkyl, di[(C1-d)alkyl]amino(C1-C4)alkyl, trifluoromethylthio, hydroxy(C1-C4)alkyl, (C1-

C4)alkoxy(C1-C4)alkyl,-C(O)R2, -C(O)0R2, -OC(O)R2, -C(O)-N(R2)2, -CH2-
C(O)R2, -CH2-C(O)OR2, -CH2-OC(O) R2, -CH2-C(O)-N(R2)2, S(O)2R2, and
S(O)2N(R2)2;
Het1 is a 3- to 8-membered, saturated or partially unsaturated monocyclic heterocyclic group comprising one or two or three ring members selected from -NR3-, -O-, -C(O)- and -S(O)p-;
R3 is either the point of attachment to X or C to give
(Formula Removed)
or R3 is selected from the group consisting of hydrogen, (C1-C4)alkyl, halo(C1-C4)alkyl, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, -C(O)(C1-C4)alkyl, -C(O)O(C1-C4)alkyl.-CH2-C(O)O(C1-C4)alkyl.-CH2-C(O)-Na((C1-C4)alkyl)2, S(O)2R2, S(O)2N(R2)2 and (C3-C8)cycloalkyl;
p is 0, 1 or 2; and
Het2 is a 5- or 6-membered aromatic heterocyclic group comprising either (a) 1 to 4 nitrogen atoms, (b) one oxygen or one sulphur atom or (c) 1 oxygen atom or 1 sulphur atom and 1 or 2 nitrogen atoms;
or a tautomer thereof, or a pharmaceutically acceptable salt or solvate of the compound of formula (I), or its tautomer;
or a compound as defined in any one of Claims 1 to 10, or a pharmaceutically acceptable salt, solvate or tautomer thereof;
for use in the treatment of pain.

17. Use of a compound of formula (I), or a pharmaceutically acceptable
salt, solvate or tautomer thereof, as defined in any of Claims 1 to 12, or 16, in the manufacture of a medicament for the treatment of pain.
18. A method of treating pain in a mammal, including a human, comprising administering to a mammal requiring such treatment an effective amount of a compound of the formula (I), or a pharmaceutically acceptable salt, solvate or tautomer thereof, as defined in anyone of Claims 1 to 12, and 16.
19. A compound of the formula
(Formula Removed)
or a pharmaceutically acceptable salt, solvate or tautomer thereof, wherein
Z is Het2 , optionally substituted on a ring carbon atom with one or more substituents selected from the group consisting of halo, cyano, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, (C3-C8)cycloalkyl, (C3-C8)cycloalkyl(C1-C4)alkyl, amino, (C1-C4)alkylamino and di(C1-C4)alkylamino; and/or Het2 is optionally substituted on a ring nitrogen atom with (C1-C4)alkyl, halo(C1-C4)alkyl and (C3-C8)cycloalkyl; with the proviso that Z is not tetrazolyl;
Y1, Y2, Y3 and Y4 are each independently CH, CR1 or N, provided that no more than two of Y1, Y2, Y3 and Y4 are N and no more than two of Y1, Y2, Y3 and Y4 are CR1;

each R1 is independently selected from the group consisting of halo, cyano,
amino, hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, hydroxy(C1-C4)alkyl, (d-
C4)alkoxy, halo(C1-C4)alkoxy, (C1-C4)alkoxy(C1-C4)alkyl, and -C(O)N(R2)2;
each R2 is independently hydrogen or (C1-C4)alkyl; or two R2 groups may be taken together with the N atom to which they are attached to form a 4- to 6-membered ring;
B is phenyl or Het2, and B is optionally substituted on a ring carbon atom with one or more substituents selected from the group consisting of halo, cyano, hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(d-C4)alkoxy, amino, (C1-C4)alkylamino, di(C1-C4)alkylamino, trifluoromethylthio, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, -C(O)OR2, -C(O)-N(R2)2, -CH2-C(O)-N(R2)2, (C3-C8)cycloalkyl, and (C3-C8)cycloalkyl(C1-C4)alkyl; and/or Het2 is optionally substituted on a ring nitrogen atom with a substituent selected from the group consisting of (C1-C4)alkyl, halo(C1-C4)alkyl, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, amino(C1-C4)alkyl, (C1-C4)alkylamino(C1-C4)alkyl and di[(C1-C4)alkyl]amino(C1-C4)alkyl;
X is absent, -O-, methylene, ethylene, methylene-O-, or -O-methylene;
C is (C3-C8)cycloalkyl, Het1, phenyl, or Het2, each optionally substituted on a ring carbon atom with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, amino, (C1-C4)alkylamino, di(C1-C4)alkylamino, trifluoromethylthio, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, -C(O)-N(R2)2, -CH2-C(O)-N(R2)2 (C3-C8)cycloalkyl, (C3-C8)cycloalkyl(C1-C4)alkyl, and D; and/or Het2 is optionally substituted on a ring nitrogen atom with a substituent selected from the group consisting of (C1-C4)alkyl, halo(C1-C4)alkyl, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, -CH2-C(O)OR2,-CH2-C(O)-N(R2)2 and D; with the proviso that C is not 3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl;

D is phenyl or benzyl, each optionally substituted with one or more substituents selected from the group consisting of halo, cyano, hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, amino, (C1-C4)alkylamino, di(C1-C4)alkylamino, trifluoromethylthio, hydroxy(C1-C4)alkyl, alkoxy(C1-C4)alkyl and -CH2-C(O)-N(R2)2;
Het1 is a 3- to 8-membered, saturated or partially unsaturated monocyclic heterocyclic group comprising one or two ring members selected from -NR3-, -O-, -C(O)- and -S(O)p-;
R3 is hydrogen, (C1-C4)alkyl, halo(C1-C4)alkyl, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, -CH2-C(O)OR2,-CH2-C(O)-N(R2)2 or D;
p is 0, 1 or 2; and
Het2 is a 5- or 6-membered aromatic heterocyclic group comprising either (a) 1 to 4 nitrogen atoms, (b) one oxygen or one sulphur atom or (c) 1 oxygen atom or 1 sulphur atom and 1 or 2 nitrogen atoms;
with the proviso that the compound of formula (I) is not the following specific compound:
(Formula Removed)
20. A compound of the formula

(Formula Removed)
or a pharmaceutically acceptable salt, solvate or tautomer thereof, wherein
Z is Het2 , optionally substituted on a ring carbon atom with one or more substituents selected from the group consisting of halo, cyano, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, (C3-C8)cycloalkyl, (C3-C8)cycloalkyl(C1-C4)alkyl, amino, (C1-C4)alkylamino and di(C1-C4)alkylamino; and/or Het2 is optionally substituted on a ring nitrogen atom with (C1-C4)alkyl, halo(C1-C4)alkyl and (C3-C8)cycloalkyl; with the proviso that Z is not tetrazolyl;
Y1, Y2, Y3 and Y4 are each independently CH, CR1 or N, provided that no more than two of Y1, Y2, Y3 and Y4 are N and no more than two of Y1, Y2, Y3 and Y4 are CR1;
each R1 is independently selected from the group consisting of halo, cyano, amino, hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, (C1-C4)alkoxy(C1-C4)alkyl, and -C(O)N(R2)2;
each R2 is independently hydrogen or (C1-C4)alkyl; or two R2 groups may be taken together with the N atom to which they are attached to form a 4- to 6-membered ring;
B is phenyl or Het2, and B is optionally substituted on a ring carbon atom with one or more substituents selected from the group consisting of halo, cyano, hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, amino, (C1-C4)alkylamino, di(C1-C4)alkylamino, trifluoromethylthio,

hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, -C(O)OR2, -C(O)-N(R2)2, -
CH2-C(O)-N(R2)2, (C3-C8)cycloalkyl, and (C3-C8)cycloalkyl(C1-C4)alkyl;
and/or Het2 is optionally substituted on a ring nitrogen atom with a
substituent selected from the group consisting of (C1-C4)alkyl, halo(C1-
C4)alkyl, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, amino(C1-C4)alkyl,
(C1-C4)alkylamino(C1-C4)alkyl and di[(C1-C4)alkyl]amino(C1-C4)alkyl;
X is absent, -O-, methylene, ethylene, methylene-O-, or -O-methylene;
C is (C3-C8)cycloalkyl, Het1, phenyl, or Het2, each optionally substituted on a ring carbon atom with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, amino, (C1-C4)alkylamino, di(C1-C4)alkylamino, trifluoromethylthio, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, -C(O)-N(R2)2, -CH2-C(O)-N(R2)2 (C3-C8)cycloalkyl, (C3-C8)cycloalkyl(C1-C4)alkyl, and D; and/or Het2 is optionally substituted on a ring nitrogen atom with a substituent selected from the group consisting of (C1-C4)alkyl, halo(C1-C4)alkyl, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, -CH2-C(O)OR2,-CH2-C(O)-N(R2)2 and D; with the proviso that C is not 3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl;
D is phenyl or benzyl, each optionally substituted with one or more substituents selected from the group consisting of halo, cyano, hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, amino, (C1-C4)alkylamino, di(C1-C4)alkylamino, trifluoromethylthio, hydroxy(C1-C4)alkyl, alkoxy(C1-C4)alkyl and -CH2-C(O)-N(R2)2;
Het1 is a 3- to 8-membered, saturated or partially unsaturated monocyclic heterocyclic group comprising one or two ring members selected from -NR3-, -O-, -C(O)- and -S(O)p-;
R3 is hydrogen, (C1-C4)alkyl, halo(C1-C4)alkyl, hydroxy(C1-C4)alkyl, (C1-d)alkoxy(C1-C4)alkyl, -CH2-C(O)OR2,-CH2-C(O)-N(R2)2 or D;

p is 0,1 or 2; and
Het2 is a 5- or 6-membered aromatic heterocyclic group comprising either (a) 1 to 4 nitrogen atoms, (b) one oxygen or one sulphur atom or (c) 1 oxygen atom or 1 sulphur atom and 1 or 2 nitrogen atoms;
or a compound as defined in any one of claims 1 to 7, or a pharmaceutically acceptable salt, solvate or tautomer thereof:
for use as a medicament.
21. A compound of the formula
(Formula Removed)
or a pharmaceutically acceptable salt, solvate or tautomer thereof, wherein
Z is Het2, optionally substituted on a ring carbon atom with one or more substituents selected from the group consisting of halo, cyano, {C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, (C3-C8)cycloalkyl, (C3-C8)cycloalkyl(d-d)alkyl, amino, (C1-C4)alkylamino and di(C1-C4)alkylamino; and/or Het2 is optionally substituted on a ring nitrogen atom with (C1-C4)alkyl, halo(C1-C4)alkyl and (C3-C8)cycloalkyl; with the proviso that Z is not tetrazolyl;
Y1, Y2, Y3 and Y4 are each independently CH, CR1 or N, provided that no more than two of Y1, Y2, Y3 and Y4 are N and no more than two of Y1, Y2, Y3 and Y4 are CR1;

each R1 is independently selected from the group consisting of halo, cyano, amino, hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, (C1-C4)alkoxy(C1-C4)alkyl, and -C(O)N(R2)2;
each R2 is independently hydrogen or (C1-C4)alkyl; or two R2 groups may be taken together with the N atom to which they are attached to form a 4- to 6-membered ring
B is phenyl or Het2, and B is optionally substituted on a ring carbon atom with one or more substituents selected from the group consisting of halo, cyano, hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, amino, (C1-C4)alkylamino, di(C1-C4)alkylamino, trifluoromethylthio, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, -C(O)OR2, -C(O)-N(R2)2, -CH2-C(O)-N(R2)2, (C3-C8)cycloalkyl, and (C3-C8)cycloalkyl(C1-C4)alkyl; and/or Het2 is optionally substituted on a ring nitrogen atom with a substituent selected from the group consisting of (C1-C4)alkyl, halo(C1-C4)alkyl, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, amino(C1-C4)alkyl, (C1-C4)alkylamino(C1-C4)alkyl and di[(C1-C4)alkyl]amino(C1-C4)alkyl;
X is absent, -O-, methylene, ethylene, methylene-O-, or -O-methylene;
C is (C3-C8)cycloalkyl, Het1, phenyl, or Het2, each optionally substituted on a ring carbon atom with one or more substituents selected from the group consisting of halogen, cyano, hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, amino, (C1-C4)alkylamino, di(C1-C4)alkylamino, trifluoromethylthio, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, -C(O)-N(R2)2) -CH2-C(O)-N(R2)2 (C3-C8)cycloalkyl, (C3-C8)cycloalkyl(C1-C4)alkyl, and D; and/or Het2 is optionally substituted on a ring nitrogen atom with a substituent selected from the group consisting of (C1-C4)alkyl, halo(C1-C4)alkyl, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, -CH2-C(O)OR2,-CH2-C(O)-N(R2)2 and D;

D is phenyl or benzyl, each optionally substituted with one or more substituents selected from the group consisting of halo, cyano, hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, amino, (C1-C4)alkylamino, di(C1-C4)alkylamino, trifluoromethylthio, hydroxy(C1-C4)alkyl, alkoxy(C1-C4)alkyl and -CH2-C(O)-N(R2)2;
Het1 is a 3- to 8-membered, saturated or partially unsaturated monocyclic heterocyclic group comprising one or two ring members selected from -NR3-, -O-, -C(O)- and -S(O)p-;
R3 is hydrogen, (C1-C4)alkyl, halo(C1-C4)alkyl, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, -CH2-C(O)OR2,-CH2-C(O)-N(R2)2 or D;
p is 0, 1 or 2; and
Het2 is a 5- or 6-membered aromatic heterocyclic group comprising either (a) 1 to 4 nitrogen atoms, (b) one oxygen or one sulphur atom or (c) 1 oxygen atom or 1 sulphur atom and 1 or 2 nitrogen atoms;
or a pharmaceutically acceptable salt, solvate or tautomer thereof:
for use in the treatment of pain.
22. A compound of formula (I):
(Formula Removed)
wherein

Z is Het2, optionally substituted on a ring carbon atom with one or more substituents selected from the group consisting of halo, cyano, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, (C3-C8)cycloalkyl, (C3-C8)cycloalkyl(C1-C4)alkyl, (C1-C4)alkyl-S-, amino, (C1-C4)alkylamino, di(C1-C4)alkylamino, amino(C1-C4)alkyl, (C1-C4)alkylamino(C1-C4)alkyl, and di[(C1-C4)alkyl]amino(C1-C4)alkyl; and/or Het2 is optionally substituted on a ring nitrogen atom with (C1-C4)alkyl, halo(C1-C4)alkyl and (C3-C8)cycloalkyl; with the proviso that Z is not tetrazolyl;
Y1, Y2, Y3 and Y4 are each independently CH, CR1 or N, provided that no more than two of Y1, Y2, Y3 and Y4 are N;
each R1 is independently selected from the group consisting of halo, cyano, amino, hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, (C1-C4)alkoxy(C1-C4)alkyl, and -C(O)N(R2)2;
each R2 is independently hydrogen, (C1-C4)alkyl, halo(C1-C4)alkyl, hydroxy(C1-C4)alkyl, or (C3-C6)cycloalkyl; or, where a nitrogen is substituted with two R2 groups, independently selected from (C1-C4)alkyl, halo(C1-C4)alkyl, or hydroxy(C1-C4)alkyl they may be taken together with the N atom to which they are attached to form a 4- to 6-membered ring;
B is phenyl or Het2, wherein, when B is Het2 it is attached to the alkoxy linker at a carbon atom, and B is optionally further substituted on a ring carbon atom with one or more substituents selected from the group consisting of halo, cyano, hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, cyano(C1-C4)aikyl, amino, (C1-C4)alkylamino, di(C1-C4)alkylamino, amino(C1-C4)alkyl, (C1-C4)alkylamino(C1-C4)alkyl, di[(C1-C4)alkyllamino(C1-C4)alkyl, trifluoromethylthio, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, -C(O)R2, -C(O)OR2, -OC(O)R2, -C(O)-N(R2)2, -CH2-C(O)R2, - CH2-C(O)OR2, -CH2-OC(O) R2, -CH2-C(O)-N(R2)2, S(O)2R2 S(O)2N(R2)2l (C3-C8)cycloalkyl, and (C3-C8)cycloalkyl(C1-C4)alkyl; and/or

Het2 is optionally substituted on a ring nitrogen atom with a substituent
selected from the group consisting of (C1-C4)alkyl, halo(C1-C4)alkyl,
hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, amino(C1-C4)alkyl, (C1-
C4)alkylamino(C1-C4)alkyl, di[(C1-C4)alkyl]amino(C1-C4)alkyl, CH2-C(O)R2, -
CH2-C(O)OR2, S(O)2R2, and S(O)2N(R2)2;
X is absent, -O-, methylene, ethylene, methylene-O-, or -O-methylene;
C is (C3-C8)cycloalkyl, Het1, phenyl, or Het2, each optionally substituted on a ring carbon atom with one or more substituents selected from the group consisting of halo, cyano, hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, (R2)2amino, (R2)2amino(C1-C4)alkyl, trifluoromethylthio, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, -C(O)R2, -C(O)OR2, -OC(O)R2, -C(O)-N(R2)2, -CH2-C(O)R2, - CH2-C(O)OR2, -CH2-OC(O) R2, -CH2-C(O)-N(R2)2, S(O)2R2, S(O)2N(R2)2, (C3-C8)cycloalkyl(C1-C4)alkyl, (C3-C8)cycloalkoxy, (C3-C8)cycloalkylamino, (C3-C8)cycloalkylamino(C1-C4)alkyl, (C3-C8)cycloalkyl(C1-C4)alkylamino, (C3-C8)cycloalkyl(C1-C4)alkylamino(C1-C4)alkyl, (C3-C8)cycloalkyl(C1-C4)alkoxy and D; and/or
Het2 is optionally substituted on a ring nitrogen atom with a substituent selected from the group consisting of hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, amino(C1-C4)alkyl, (C1-C4)alkylamino(C1-C4)alkyl, di[(C1-C4)alkyl]amino(C1-C4)alkyl, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, -C(O)R2, -C(O)OR2, CH2-C(O)R2, -CH2-C(O)OR2,-CH2-C(O)-N(R2)2, S(O)2R2, and S(O)2N(R2)2 and D;
with the proviso that C is not 3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl;
D is phenyl, benzyl, (C3-C8)cycloalkyl, or Het1, each optionally substituted on a carbon atom with one or more substituents independently selected from the group consisting of halo, cyano, hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, amino, (C1-C4)alkylamino, di(C1-C4)alkylamino, amino(C1-C4)alkyl, (C1-C4)alkylamino(C1-C4)alkyl, di[(C1-C4)alkyl]amino(C1-C4)alkyl, trifluoromethylthio, hydroxy(C1-C4)alkyl, (C1-

C4)alkoxy(C1-C4)alkyl,-C(O)R2, -C(O)OR2, -OC(O)R2, -C(O)-N(R2)2, -CH2-
C(O)R2, - CH2-C(O)OR2, -CH2-OC(O) R2, -CH2-C(O)-N(R2)2, S(O)2R2, and
S(O)2N(R2)2;
Het1 is a 3- to 8-membered, saturated or partially unsaturated monocyclic heterocyclic group comprising one or two or three ring members selected from -NR3-, -O-, -C(O)- and -S(O)p-;
R3 is either the point of attachment to X or C; or is selected from the group consisting of hydrogen, (C1-C4)alkyl, halo(C1-C4)alkyl, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, -C(O)(C1-C4)alkyl, -C(O)O(C1-C4)alkyl, -CH2-C(O)O(C1-C4)alkyl, -CH2-C(O)-N((C1-C4)alkyl)2, S(O)2R2, S(O)2N(R2)2 and (C3-C8)cycloalkyl;
p is 0,1 or 2; and
Het2 is a 5- or 6-membered aromatic heterocyclic group comprising either (a) 1 to 4 nitrogen atoms, (b) one oxygen or one sulphur atom or (c) 1 oxygen atom or 1 sulphur atom and 1 or 2 nitrogen atoms;
or a tautomer thereof, or a pharmaceutically acceptable salt or solvate of the compound of formula (I), or its tautomer;
with the proviso that the compound of formula (I) is not the following specific compound:
(Formula Removed)
23. A compound of formula (I):

(Formula Removed)
wherein
Z is Het2, optionally substituted on a ring carbon atom with one or more substituents selected from the group consisting of halo, cyano, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, ha!o(C1-C4)alkoxy, (C3-C8)cycloalkyl, (C3-C8)cycloalkyl(C1-C4)alkyl, (C1-C4)alkyl-S-, amino, (C1-C4)alkylamino, di(C1-C4)alkylamino, amino(C1-C4)alkyl, (C1-C4)alkylamino(C1-C4)alkyl, and di[(C1-C4)alkyl]amino(C1-C4)alkyl; and/or Het2 is optionally substituted on a ring nitrogen atom with (C1-C4)alkyl, halo(C1-C4)alkyl and (C3-C8)cycloalkyl; with the proviso that Z is not tetrazolyl;
Y1, Y2, Y3 and Y4 are each independently CH, CR1 or N, provided that no more than two of Y1, Y2, Y3 and Y4 are N;
each R1 is independently selected from the group consisting of halo, cyano, amino, hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, (C1-C4)alkoxy(C1-C4)alkyl, and -C(O)N(R2)2;
each R2 is independently hydrogen, (C1-C4)alkyl, halo(C1-C4)alkyl, hydroxy(C1-C4)alkyl, or (C3-C6)cycloalkyl; or, where a nitrogen is substituted with two R2 groups, independently selected from (C1-C4)alkyl, halo(C1-C4)alkyl, or hydroxy(C1-C4)alkyl they may be taken together with the N atom to which they are attached to form a 4- to 6-membered ring;
B is phenyl or Het2, wherein, when B is Het2 it is attached to the alkoxy linker at a carbon atom, and B is optionally further substituted on a ring carbon

atom with one or more substituents selected from the group consisting of
halo, cyano, hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, (d-d)alkoxy, halo(C1-
C4)alkoxy, cyano(C1-C4)alkyl, amino, (d-d)alkylamino, di(C1-C4)alkylamino,
amino(C1-C4)alkyl, (C1-C4)alkylamino(C1-C4)alkyl, di[(C1-C4)alkyl]amino(C1-
C4)alkyl, trifluoromethylthio, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, -
C(O)R2, -C(O)OR2, -OC(O)R2, -C(O)-N(R2)2, -CH2-C(O)R2, - CH2-C(O)OR2,
-CH2-OC(O) R2, -CH2-C(O)-N(R2)2, S(O)2R2, S(O)2N(R2)2, (C3-C8)cycloalkyl,
and (C3-C8)cycloalkyl(C1-C4)alkyl; and/or
Het2 is optionally substituted on a ring nitrogen atom with a substituent
selected from the group consisting of (C1-C4)alkyl, halo(C1-C4)alkyl,
hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, amino(C1-C4)alkyl, (C1-
d)alkylamino(C1-C4)alkyl, di[(d-d)alkyl]amino(d-d)alkyl, CH2-C(O)R2, -
CH2-C(O)OR2, S(O)2R2, and S(O)2N(R2)2;
X is absent, -O-, methylene, ethylene, methylene-O-, or -O-methylene;
C is (C3-C8)cycloalkyl, Het1, phenyl, or Het2, each optionally substituted on a ring carbon atom with one or more substituents selected from the group consisting of halo, cyano, hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-d)alkoxy, halo(C1-C4)alkoxy, (R2)2amino, (R2)2amino(C1-C4)alkyl, trifluoromethylthio, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, -C(O)R2, -C(O)OR2, -OC(O)R2, -C(O)-N(R2)2, -CH2-C(O)R2, - CH2-C(O)OR2, -CH2-OC(O) R2, -CH2-C(O)-N(R2)2, S(O)2R2, S(O)2N(R2)2, (C3-C8)cycloalkyl(C1-C4)alkyl, (C3-C8)cycloalkoxy, (C3-C8)cycloalkylamino, (C3-C8)cycloalkylamino(C1-C4)alkyl, (C3-C8)cycloalkyl(d-d)alkylamino, (C3-C8)cycloalkyl(C1-C4)alkylamino(C1-C4)alkyl, (C3-C8)cycloalkyl(C1-C4)alkoxy and D; and/or
Het2 is optionally substituted on a ring nitrogen atom with a substituent selected from the group consisting of hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, amino(C1-C4)alkyl,(C1-C4)alkylamino(C1-C4)alkyl, di[(C1-C4)alkyl]amino(C1-C4)alkyl, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, -C(O)R2, -C(O)OR2, CH2-C(O)R2, -CH2-C(O)OR2,-CH2-C(O)-N(R2)2, S(O)2R2, and S(O)2N(R2)2 and D;

with the proviso that C is not 3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl;
D is phenyl, benzyl, (C3-C8)cycloalkyl, or Het1, each optionally substituted on a carbon atom with one or more substituents independently selected from the group consisting of halo, cyano, hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, amino, (C1-C4)alkylamino, di(C1-C4)alkylamino, amino(C1-C4)alkyl, (C1-C4)alkylamino(C1-C4)alkyl, di[(C1-C4)alkyl]amino(C1-C4)alkyl, trifluoromethylthio, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl,-C(O)R2, -C(O)OR2, -OC(O)R2, -C(O)-N(R2)2, -CH2-C(O)R2, - CH2-C(O)OR2, -CH2-OC(O) R2, -CH2-C(O)-N(R2)2, S(O)2R2, and S(O)2N(R2)2;
Het1 is a 3- to 8-membered, saturated or partially unsaturated monocyclic heterocyclic group comprising one or two or three ring members selected from -NR3-, -O-, -C(O)- and -S(O)p-;
R3 is either the point of attachment to X or C; or is selected from the group consisting of hydrogen, (C1-C4)alkyl, halo(C1-C4)alkyl, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, -C(O)(C1-C4)alkyl, -C(O)O(C1-C4)alkyl, -CH2-C(O)O(C1-C4)alkyl, -CH2-C(O)-N((C1-C4)alkyl)2, S(O)2R2, S(O)2N(R2)2 and (C3-C8)cycloalkyl;
p is 0,1 or 2; and
Het2 is a 5- or 6-membered aromatic heterocyclic group comprising either (a) 1 to 4 nitrogen atoms, (b) one oxygen or one sulphur atom or (c) 1 oxygen atom or 1 sulphur atom and 1 or 2 nitrogen atoms;
or a tautomer thereof, or a pharmaceutically acceptable salt or solvate of the compound of formula (I), or its tautomer;
for use as a medicament.

24. A compound of formula (I):
(Formula Removed)
wherein
Z is Het2, optionally substituted on a ring carbon atom with one or more substituents selected from the group consisting of halo, cyano, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, (C3-C8)cycloalkyl, (C3-C8)cycloalkyl(C1-C4)alkyl, (C1-C4)alkyl-S-, amino, (C1-C4)alkylamino, di(C1-C4)alkylamino, amino(C1-C4)alkyl, (C1-C4)alkylamino(C1-C4)alkyl, and di[(C1-C4)alkyl]amino(C1-C4)alkyl; and/or Het2 is optionally substituted on a ring nitrogen atom with (C1-C4)alkyl, halo(C1-C4)alkyl and (C3-C8)cycloalkyl; with the proviso that Z is not tetrazolyl;
Y1, Y2, Y3 and Y4 are each independently CH, CR1 or N, provided that no more than two of Y1, Y2, Y3 and Y4 are N;
each R1 is independently selected from the group consisting of halo, cyano, amino, hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, (C1-C4)alkoxy(C1-C4)alkyl, and -C(O)N(R2)2;
each R2 is independently hydrogen, (C1-C4)alkyl, halo(d-d)alkyl, hydroxy(C1-C4)alkyl, or (C3-C6)cycloalkyl; or, where a nitrogen is substituted with two R2 groups, independently selected from (C1-C4)alkyl, halo(d-C4)alkyl, or hydroxy(C1-C4)alkyl they may be taken together with the N atom to which they are attached to form a 4- to 6-membered ring;

B is phenyl or Het2, wherein, when B is Het2 it is attached to the alkoxy linker
at a carbon atom, and B is optionally further substituted on a ring carbon
atom with one or more substituents selected from the group consisting of
halo, cyano, hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-
C4)alkoxy, cyano(C1-C4)alkyl, amino, (C1-C4)alkylamino, di(C1-C4)alkylamino,
amino(C1-C4)alkyl, (C1-C4)alkylamino(C1-C4)alkyl, di[(C1-C4)alkyl]amino(C1-
C4)alkyl, trifluoromethylthio, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, -
C(O)R2, -C(O)OR2, -OC(O)R2, -C(O)-N(R2)2, -CH2-C(O)R2, - CH2-C(O)OR2,
-CH2-OC(O) R2, -CH2-C(O)-N(R2)2, S(O)2R2, S(O)2N(R2)2, (C3-C8)cycloalkyl,
and (C3-C8)cycloalkyl(C1-C4)alkyl; and/or
Het2 is optionally substituted on a ring nitrogen atom with a substituent
selected from the group consisting of (C1-C4)alkyl, halo(C1-C4)alkyl,
hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, amino(C1-C4)alkyl, (C1-
C4)alkylamino(C1-C4)alkyl, di[(C1-C4)alkyl]amino(C1-C4)alkyl, CH2-C(O)R2, -
CH2-C(O)OR2, S(O)2R2, and S(O)2N(R2)2;
X is absent, -O-, methylene, ethylene, methylene-O-, or -O-methylene;
C is (C3-C8)cycloalkyl, Het1, phenyl, or Het2, each optionally substituted on a ring carbon atom with one or more substituents selected from the group consisting of halo, cyano, hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, (R2)2amino, (R2)2amino(C1-C4)alkyl, trifluoromethylthio, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, -C(O)R2, -C(O)OR2, -OC(O)R2, -C(O)-N(R2)2, -CH2-C(O)R2, - CH2-C(O)OR2, -CH2-OC(O) R2, -CH2-C(O)-N(R2)2, S(O)2R2, S(O)2N(R2)2l (C3-C8)cycloalkyl(Cr C4)alkyl, (C3-C8)cycloalkoxy, (C3-C8)cycloalkylamino, (C3-C8)cycloalkylamino(C1-C4)alkyl, (C3-C8)cycloalkyl(C1-C4)alkylamino, (C3-C8)cycloalkyl(C1-C4)alkylamino(C1-C4)alkyl, (C3-C8)cycloalkyl(C1-C4)alkoxy and D; and/or
Het2 is optionally substituted on a ring nitrogen atom with a substituent selected from the group consisting of hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, amino(C1-C4)alkyl, (C1-C4)alkylamino(C1-C4)alkyl, di[(C1-C4)alkyl]amino(C1-C4)alkyl, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, -C(O)R2, -C(O)OR2,

CH2-C(O)R2, -CH2-C(O)OR2 ,-CH2-C(O)-N(R2)2l S(O)2R2, and S(O)2N(R2)2
and D; with the proviso that C is not 3,5-dioxo-4,5-dihydro-3H-[1,2,4]triazin-2-yl;
D is phenyl, benzyl, (C3-C8)cycloalkyl, or Het1, each optionally substituted on a carbon atom with one or more substituents independently selected from the group consisting of halo, cyano, hydroxy, (C1-C4)alkyl, halo(C1-C4)alkyl, (C1-C4)alkoxy, halo(C1-C4)alkoxy, amino, (C1-C4)alkylamino, di(C1-C4)alkylamino, amino(C1-C4)alkyl, (C1-C4)alkylamino(C1-C4)alkyl, di[(C1-C4)alkyl]amino(C1-C4)alkyl, trifluoromethylthio, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl,-C(O)R2, -C(O)OR2, -OC(O)R2. -C(O)-N(R2)2, -CH2-C(O)R2, - CH2-C(O)OR2, -CH2-OC(O) R2, -CH2-C(O)-N(R2)2, S(O)2R2, and S(O)2N(R2)2;
Het1 is a 3- to 8-membered, saturated or partially unsaturated monocyclic heterocyclic group comprising one or two or three ring members selected from -NR3-, -O-, -C(O)- and -S(O)p-;
R3 is either the point of attachment to X or C; or is selected from the group consisting of hydrogen, (C1-C4)alkyl, halo(C1-C4)alkyl, hydroxy(C1-C4)alkyl, (C1-C4)alkoxy(C1-C4)alkyl, -C(O)(C1-C4)alkyl, -C(O)O(C1-C4)alkyl, -CH2-C(O)0(C1-C4)alkyl, -CH2-C(O)-N((C1-C4)alkyl)2, S(O)2R2l S(O)2N(R2)2 and (C3-C8)cycloalkyl;
p is 0,1 or 2; and
Het2 is a 5- or 6-membered aromatic heterocyclic group comprising either (a) 1 to 4 nitrogen atoms, (b) one oxygen or one sulphur atom or (c) 1 oxygen atom or 1 sulphur atom and 1 or 2 nitrogen atoms;
or a tautomer thereof, or a pharmaceutically acceptable salt or solvate of the compound of formula (I), or its tautomer;

for use in the treatment of pain.
25. The compound 4-[2-(5-amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-
chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide;
or a pharmaceutically acceptable salt, solvate or tautomer thereof thereof.
26. The compound 4-[2-(2-aminopyridin-4-yl)-4-chlorophenoxy]-5-
chloro-2-fluoro-N-pyridazin-3-ylbenzenesulfonamide;
or a pharmaceutically acceptable salt, solvate or tautomer thereof thereof.
27. The compound 4-[2-(3-amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-
chloro-2-fluoro-N-pyrimidin-2-ylbenzenesulfonamide;
or a pharmaceutically acceptable salt, solvate or tautomer thereof thereof.